|Bid||205.71 x 900|
|Ask||206.19 x 1100|
|Day's range||200.00 - 206.33|
|52-week range||186.83 - 369.69|
|Beta (5Y monthly)||1.17|
|PE ratio (TTM)||44.44|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
With its shares down by more than 33% in the past 12 months, Intuitive Surgical (NASDAQ: ISRG) has been hammered by the brutal bear market. Despite rising revenue and earnings over the last three years, the robotic surgery company's margins are still below their pre-pandemic level, and the market's sour sentiment toward growth stocks certainly isn't helping to boost its share price. In fact, Intuitive's valuation might well be approaching a point where investors will start to pile into the stock once again, assuming that they believe more growth is still on the way.
The FDA clears the integration of mobile cone-beam CT imaging technology with Intuitive's (ISRG) Ion Endoluminal System, enhancing a physician's ability to provide minimally invasive lung biopsy.
Businesses in evolving or growing industries are attractive to investors because of their growth prospects. In the healthcare sector, robotic surgery giant Intuitive Surgical (NASDAQ: ISRG), medical devices manufacturer and distributor Medtronic (NYSE: MDT), and multi-state cannabis operator Cresco Labs (OTC: CRLBF) are rising stars with bright prospects. While all three have established a name in their respective fields, they are constantly looking for further growth opportunities.